CHARLOTTESVILLE, Va., Jan. 19 /PRNewswire/ -- Adenosine Therapeutics, LLC, announced today it has signed a worldwide collaboration and option agreement with Ortho-McNeil Pharmaceutical, Inc. to further develop A2B adenosine receptor antagonist compounds for the potential treatment of Type II diabetes, asthma and other disorders.